Digestive System Neoplasm
NCI Definition: A benign or malignant neoplasm involving any part of the digestive system. 
Digestive system neoplasms most frequently harbor alterations in TP53, KRAS, APC, SMAD4, and PIK3CA .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in digestive system neoplasm .
There is 1 clinical trial for digestive system neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains digestive system neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
Aldesleukin, cyclophosphamide, and fludarabine are the most common interventions in digestive system neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.